Pyrantel Pamoate (Pyrantel Embonate)

Verify with FDA CVM →

502 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
502
Total Reports
72
Deaths Reported
1430.0%
Death Rate

Active Ingredients

Pyrantel Pamoate (Pyrantel Embonate)

Administration Routes

OralUnknownSubcutaneous

Species Affected

Dog 385
Cat 57
Unknown 30
Horse 29
Goat 1

Most Affected Breeds

Retriever - Labrador 40
Dog (unknown) 38
Domestic Shorthair 32
Unknown 30
Chihuahua 22
Terrier - Yorkshire 18
Retriever - Golden 14
Terrier - Bull - American Pit 13
Shepherd Dog - German 12
Beagle 11

Most Reported Reactions

Vomiting 90
Lethargy (see also Central nervous system depression in 'Neurological') 77
Diarrhoea 73
Lack of efficacy (endoparasite) - hookworm 57
Death 50
Facial swelling (see also 'Skin') 38
Anorexia 36
INEFFECTIVE, ASCARIDS NOS 27
Anaphylactoid reaction 26
Lack of efficacy (endoparasite) - roundworm NOS 26
Seizure NOS 21
Fever 21

Outcome Breakdown

Ongoing
154 (31.7%)
Outcome Unknown
150 (30.9%)
Recovered/Normal
109 (22.4%)
Died
56 (11.5%)
Euthanized
17 (3.5%)

Data Summary

Metric Value
Total adverse event reports 502
Reports involving death 72
Case-fatality rate (reported events) 1430.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Pyrantel Pamoate (Pyrantel Embonate) Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 502 adverse event reports referencing Pyrantel Pamoate (Pyrantel Embonate), including 72 reports in which the animal died — a 1430.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Pyrantel Pamoate (Pyrantel Embonate). Reported administration routes include Oral, Unknown, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Pyrantel Pamoate (Pyrantel Embonate) reports are Dog (385 reports), Cat (57 reports), Unknown (30 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (40), Dog (unknown) (38), Domestic Shorthair (32) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Pyrantel Pamoate (Pyrantel Embonate) are Vomiting (90), Lethargy (see also Central nervous system depression in 'Neurological') (77), Diarrhoea (73), Lack of efficacy (endoparasite) - hookworm (57). Of the 486 reports with a coded outcome, Ongoing is the leading category at 31.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Pyrantel Pamoate (Pyrantel Embonate).

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial